Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 16, 2026 is 3.71 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 2.59 % — a change of 43.56% (higher).

EBIT/Assets

3.71 %

YoY

43.56%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Vcanbio Cell & Gene Engineering Corp is 2025 3.71 % . Operating Income to Assets Ratio (EBIT/Assets) of Vcanbio Cell & Gene Engineering Corp was 2024 2.59 % . It decreases by 43.56% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
0.99 CNY
Jan 1, 2019
2.35 CNY
Jan 1, 2020
-1.90 CNY
Jan 1, 2021
4.37 CNY
Jan 1, 2022
2.95 CNY
Jan 1, 2023
2.42 CNY
Jan 1, 2024
2.59 CNY
Jan 1, 2025
3.71 CNY
The Vcanbio Cell & Gene Engineering Corp EBIT/Assets history
YEAREBIT/AssetsYoY
3.71 %+43.56%
2.59 %+6.76%
2.42 %-17.92%
2.95 %-32.40%
4.37 %-329.89%
-1.90 %-180.87%
2.35 %+136.35%
0.99 %-52.46%
2.09 %-25.29%
2.80 %-68.78%
8.96 %+281.06%
2.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Operating Income to Assets Ratio (EBIT/Assets) of Vcanbio Cell & Gene Engineering Corp is 3.71 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Vcanbio Cell & Gene Engineering Corp changed from 2.59 % to 3.71 %, representing a 43.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Vcanbio Cell & Gene Engineering Corp

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Vcanbio Cell & Gene Engineering Corp